[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601908":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":126,"collaborators":19,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":19,"eligibilityCriteria":134,"healthyVolunteers":130,"sex":135,"minAge":136,"maxAge":19,"enrollmentInfo":137,"targetDuration":19,"studyType":140,"phases":141,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"ModernaTX, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mRNA-2808","EXPERIMENTAL","Participants will receive mRNA-2808.",[13],"Drug: mRNA-2808",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","intravenous",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Moderna WeCare Team","CONTACT","+1-866-663-3762","WeCareClinicalTrials@modernatx.com",[27,41,51,61,71,80,86,96,106,116],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"University of Alabama at Birmingham Hospital","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-86.80249,33.52066,{"lat":39,"lon":38},{"facility":42,"status":29,"city":43,"state":44,"zip":45,"country":33,"countryCode":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":19},"UCSF","San Francisco","California","94143",{"type":36,"coordinates":47},[48,49],-122.41942,37.77493,{"lat":49,"lon":48},{"facility":52,"status":29,"city":53,"state":54,"zip":55,"country":33,"countryCode":34,"cosmosGeoPoint":56,"geoPoint":60,"contacts":19},"Emory University Hospital","Atlanta","Georgia","30322",{"type":36,"coordinates":57},[58,59],-84.38798,33.749,{"lat":59,"lon":58},{"facility":62,"status":29,"city":63,"state":64,"zip":65,"country":33,"countryCode":34,"cosmosGeoPoint":66,"geoPoint":70,"contacts":19},"Mass General Brigham","Boston","Massachusetts","02114",{"type":36,"coordinates":67},[68,69],-71.05977,42.35843,{"lat":69,"lon":68},{"facility":72,"status":29,"city":73,"state":73,"zip":74,"country":33,"countryCode":34,"cosmosGeoPoint":75,"geoPoint":79,"contacts":19},"Tisch Cancer Institute at Mount Sinai","New York","10029",{"type":36,"coordinates":76},[77,78],-74.00597,40.71427,{"lat":78,"lon":77},{"facility":81,"status":29,"city":73,"state":73,"zip":82,"country":33,"countryCode":34,"cosmosGeoPoint":83,"geoPoint":85,"contacts":19},"Memorial Sloan-Kettering Cancer Center","10065",{"type":36,"coordinates":84},[77,78],{"lat":78,"lon":77},{"facility":87,"status":29,"city":88,"state":89,"zip":90,"country":33,"countryCode":34,"cosmosGeoPoint":91,"geoPoint":95,"contacts":19},"Atrium Health Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":36,"coordinates":92},[93,94],-80.84313,35.22709,{"lat":94,"lon":93},{"facility":97,"status":29,"city":98,"state":99,"zip":100,"country":33,"countryCode":34,"cosmosGeoPoint":101,"geoPoint":105,"contacts":19},"Penn Medicine","Philadelphia","Pennsylvania","19104",{"type":36,"coordinates":102},[103,104],-75.16362,39.95238,{"lat":104,"lon":103},{"facility":107,"status":29,"city":108,"state":109,"zip":110,"country":33,"countryCode":34,"cosmosGeoPoint":111,"geoPoint":115,"contacts":19},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":36,"coordinates":112},[113,114],-86.78444,36.16589,{"lat":114,"lon":113},{"facility":117,"status":29,"city":118,"state":119,"zip":120,"country":33,"countryCode":34,"cosmosGeoPoint":121,"geoPoint":125,"contacts":19},"The Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":36,"coordinates":122},[123,124],-87.90647,43.0389,{"lat":124,"lon":123},{"type":127,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100601908","phase-1-a-study-of-mrna-2808-in-participants-with-relapsed-or-refractory-multiple-myeloma-100601908",false,"NCT07116616","A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 1\u002F2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","Key Inclusion Criteria:\n\n* RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody.\n* Measurable disease defined as at least 1 of the following:\n\n  * Serum M-protein ≥0.5 grams\u002Fdeciliter\n  * Urine M-protein ≥200 milligrams (mg)\u002F24-hour\n  * Involved free light chain (FLC) ≥100 mg\u002Fliter and an abnormal FLC ratio\n  * Plasmacytoma with a single diameter ≥2 centimeters\n  * Bone marrow plasma cells \\>30%\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement of myeloma.\n* Active plasma cell leukemia, defined as peripheral blood plasma cells ≥20%.\n* Radiotherapy or cytotoxic chemotherapy within 2 weeks prior to Day 1 (Baseline), except palliative radiotherapy of limited field is permissible within 2 weeks after discussion with the Sponsor medical monitor.\n* Antibody-based immunotherapy (monoclonal antibody, bispecific antibody, antibody drug conjugate) within 21 days prior to Day 1 (Baseline).\n* Proteasome inhibitor therapy or immunomodulatory agent within 14 days prior to Day 1 (Baseline).\n* Autologous hematopoietic cell transplant within 100 days prior to Day 1 (Baseline).\n* Allogeneic hematopoietic cell transplant within 180 days prior to Day 1 (Baseline).\n* Genetically modified adoptive autologous or allogeneic cellular therapy (for example, chimeric antigen receptor T cell, chimeric antigen receptor natural killer) within 12 weeks prior to Day 1 (Baseline).\n* Corticosteroid therapy ≥140 mg prednisone or equivalent cumulative dose within 14 days prior to Day 1 (Baseline).\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":138,"type":139},166,"ESTIMATED","INTERVENTIONAL",[142,143],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).",[146],"Relapsed or Refractory Multiple Myeloma",[148,149,150,151],"relapsed or refractory multiple myeloma","RRMM","multiple myeloma","MM","2026-07-22",{"date":154,"type":155},"2026-07-24","ACTUAL",{"date":157,"type":155},"2025-09-30",{"date":159,"type":139},"2032-06-17",{"name":5,"class":6},10]